文献速递临床试验与 GCP基础与转化研究

高密度微阵列贴片流感疫苗的I期随机对照试验:安全性、耐受性与免疫原性

Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
PubMed 文献 · PLoS Med · 2020-03-17

该I期随机对照试验在澳大利亚墨尔本纳入60名健康成人(18-35岁)进行A部分研究,随后追加150名成人随机分入9组,评估高密度微阵列贴片(HD-MAP)递送单价流感疫苗的安全性、耐受性和免疫原性。结果显示HD-MAP接种安全耐受,局部和全身不良事件多为轻中度;2.5 μg血凝素(HA)经HD-MAP递送诱导的血凝抑制(HAI)和微量中和(MN)滴度与15 μg HA肌内注射无显著差异,且部分HD-MAP组HAI几何平均滴度(GMT)显著高于肌内注射四价流感疫苗(QIV)。

要点

  • HD-MAP递送流感疫苗安全耐受,不良事件多为轻中度。
  • 2.5 μg HA经HD-MAP诱导的HAI和MN滴度与15 μg HA肌内注射相当。
  • 部分HD-MAP组第8天和第22天HAI GMT显著高于IM-QIV-15组。

核心结论

  • HD-MAP递送流感疫苗安全耐受,免疫应答与肌内注射相似或显著增强。
  • 2.5 μg HA(标准剂量的1/6)经HD-MAP诱导的HAI和MN滴度与15 μg HA肌内注射无显著差异。

研究设计与样本

  • I期随机对照试验,A部分60名健康成人(18-35岁)接种HD-MAP或肌内注射,B部分再纳入150名成人随机分入9组(每组20人)。
  • 主要目标为安全性和耐受性,次要目标为免疫原性,评估至接种后60天。
  • 另有两组(每组5人)用于活检分析HD-MAP应用部位的细胞组成,不纳入主要安全性和免疫学分析。

主要发现

  • HD-MAP接种后全身不良事件主要为头痛或肌痛,局部不良事件为接种部位反应,通常为红斑。
  • 第8天HAI GMT:MAP-UA-15组242.5(95%CI 133.2-441.5,p=0.02)、MAP-FA-15组218.6(95%CI 111.9-427.0,p=0.04)、MAP-FA-10组437.1(95%CI 254.3-751.3,p<0.001),均高于IM-QIV-15组82.8(95%CI 42.4-161.8)。
  • 第22天HAI GMT:MAP-FA-10组485.0(95%CI 301.5-780.2,p=0.001)、MAP-UA-15组367.6(95%CI 197.9-682.7,p=0.02),均高于IM-QIV-15组139.3(95%CI 79.3-244.5)。
  • 探索性免疫分析显示HD-MAP递送诱导的免疫应答总体与肌内注射QIV相似或更高。
  • HD-MAP包被的疫苗在40°C储存至少12个月抗原性稳定。

关键数值与推荐

  • HD-MAP递送2.5 μg HA诱导的HAI和MN滴度与15 μg HA肌内注射无显著差异。
  • HD-MAP接种安全耐受,全身和局部不良事件均为轻中度。
  • HD-MAP包被疫苗在40°C储存至少12个月抗原性稳定。

临床怎么用

  • HD-MAP可能提供无需针头的流感疫苗接种方式,且低剂量(2.5 μg HA)即可诱导与标准肌内注射剂量相当的免疫应答。
  • HD-MAP疫苗在40°C下稳定至少12个月,可能改善疫苗热稳定性。

局限性

  • 研究组样本量小。
  • 使用的是单价流感疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Vaxxas high-density microarray patch (HD-MAP) consists of a high density of microprojections coated with vaccine for delivery into the skin. Microarray patches (MAPs) offer the possibility of improved vaccine thermostability as well as the potential to be safer, more acceptable, easier to use, and more cost-effective for the administration of vaccines than injection by needle and syringe (N&S). Here, we report a phase I trial using the Vaxxas HD-MAP to deliver a monovalent influenza vaccine that was to the best of our knowledge the first clinical trial to evaluate the safety, tolerability, and immunogenicity of lower doses of influenza vaccine delivered by MAPs. METHODS AND FINDINGS: HD-MAPs were coated with a monovalent, split inactivated influenza virus vaccine containing A/Singapore/GP1908/2015 H1N1 haemagglutinin (HA). Between February 2018 and March 2018, 60 healthy adults (age 18-35 years) in Melbourne, Australia were enrolled into part A of the study and vaccinated with either: HD-MAPs delivering 15 μg of A/Singapore/GP1908/2015 H1N1 HA antigen (A-Sing) to the volar forearm (FA); uncoated HD-MAPs; intramuscular (IM) injection of commercially available quadrivalent influenza vaccine (QIV) containing A/Singapore/GP1908/2015 H1N1 HA (15 μg/dose); or IM injection of H1N1 HA antigen (15 μg/dose). After 22 days' follow-up and assessment of the safety data, a further 150 healthy adults were enrolled and randomly assigned to 1 of 9 treatment groups. Participants (20 per group) were vaccinated with HD-MAPs delivering doses of 15, 10, 5, 2.5, or 0 μg of HA to the FA or 15 μg HA to the upper arm (UA), or IM injection of QIV. The primary objectives of the study were safety and tolerability. Secondary objectives were to assess the immunogenicity of the influenza vaccine delivered by HD-MAP. Primary and secondary objectives were assessed for up to 60 days post-vaccination. Clinical staff and participants were blind as to which HD-MAP treatment was administered and to administration of IM-QIV-15 or IM-A/Sing-15. All laboratory investigators were blind to treatment and participant allocation. Two further groups in part B (5 participants per group), not included in the main safety and immunological analysis, received HD-MAPs delivering 15 μg HA or uncoated HD-MAPs applied to the forearm. Biopsies were taken on days 1 and 4 for analysis of the cellular composition from the HD-MAP application sites. The vaccine coated onto HD-MAPs was antigenically stable when stored at 40°C for at least 12 months. HD-MAP vaccination was safe and well tolerated; any systemic or local adverse events (AEs) were mild or moderate. Observed systemic AEs were mostly headache or myalgia, and local AEs were application-site reactions, usually erythema. HD-MAP administration of 2.5 μg HA induced haemagglutination inhibition (HAI) and microneutralisation (MN) titres that were not significantly different to those induced by 15 μg HA injected IM (IM-QIV-15). HD-MAP delivery resulted in enhanced humoral responses compared with IM injection with higher HAI geometric mean titres (GMTs) at day 8 in the MAP-UA-15 (GMT 242.5, 95% CI 133.2-441.5), MAP-FA-15 (GMT 218.6, 95% CI 111.9-427.0), and MAP-FA-10 (GMT 437.1, 95% CI 254.3-751.3) groups compared with IM-QIV-15 (GMT 82.8, 95% CI 42.4-161.8), p = 0.02, p = 0.04, p < 0.001 for MAP-UA-15, MAP-FA-15, and MAP-FA-10, respectively. Higher titres were also observed at day 22 in the MAP-FA-10 (GMT 485.0, 95% CI 301.5-780.2, p = 0.001) and MAP-UA-15 (367.6, 95% CI 197.9-682.7, p = 0.02) groups compared with the IM-QIV-15 group (GMT 139.3, 95% CI 79.3-244.5). Results from a panel of exploratory immunoassays (antibody-dependent cellular cytotoxicity, CD4+ T-cell cytokine production, memory B cell (MBC) activation, and recognition of non-vaccine strains) indicated that, overall, Vaxxas HD-MAP delivery induced immune responses that were similar to, or higher than, those induced by IM injection of QIV. The small group sizes and use of a monovalent influenza vaccine were limitations of the study. CONCLUSIONS: Influenza vaccine coated onto the HD-MAP was stable stored at temperatures up to 40°C. Vaccination using the HD-MAP was safe and well tolerated and resulted in immune responses that were similar to or significantly enhanced compared with IM injection. Using the HD-MAP, a 2.5 μg dose (1/6 of the standard dose) induced HAI and MN titres similar to those induced by 15 μg HA injected IM. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR.org.au), trial ID 108 ACTRN12618000112268/U1111-1207-3550.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Forster AH, Witham K, Depelsenaire ACI, et al. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial. PLoS Med. 2020. PMID: 32181756. doi:10.1371/journal.pmed.1003024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。